Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy

Climacteric

Volumn 6, Issue 2, 2003, Pages 146-150

  Yenen, M C ^a   Dede, M ^a   Goktolga, U ^a   Kucuk T ^a   Pabuccu R ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Fibrocystic mastopathy; Hormone replacement therapy; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; BREAST HYPERPLASIA; CANCER RISK; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBROCYSTIC BREAST DISEASE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTITUTION THERAPY;

EID: 0038131731     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/713605375     Document Type: Article

References (14)

1. Cole P, Elwood JM, Kaplan SD. Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol 1978;108:112
2. Hislop TJ, Elwood JM. Risk factors for benign breast disease. A 30 years cohort study. Can Med Assoc J 1981;124:283
3. Angeli A, Dogliotti L, Naldoni C, et al. Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk. J Steroid Biochem Mol Biol 1994;49:333-9
4. Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999;353:1742-5
5. Plu-Bureau G, Thalabard JC. It is not advisable to prescribe hormonal replacement therapy to a woman with proliferative mastopathy with atypia. Gynecol Obstet Fertil 2002;30:335-9
6. Espie M, Cuvier C, Perret F, Cottu PH. It is possible to prescribe a hormonal replacement therapy for a woman with proliferative mastopathy with atypia. Gynecol Obstet Fertil 2002;30:331-5
7. Erel CT, Erel G, Seyisoglu H, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151-7
8. Sendag F, Terek MC, Ozsener S, et al. Mammographic density changes during postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-50
9. Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165-71
10. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002;41:171-5
11. Van Gils CH, Otten JDM, Verbeek ALM, Hendriks JHCL, Holland R. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmergen, The Netherlands. J Epidemiol Community Health 1998;52:267-71
12. Isabel J, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estradiol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101-7
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in heathy postmenopausal women. J Am Med Assoc 2002;288:321-33
14. Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-9